Icelandic Salmon (ISLAX) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
14 Jan, 2026Executive summary
Operations stabilized in Q3 2024 after earlier biological challenges, with improved biological control, increased smolt releases, and investments in smolt facilities supporting future growth.
Harvested 1,750 tonnes in Q3 2024, down from 4,040 tonnes in Q3 2023, due to MAB optimization and prior sea lice issues.
EBIT for Q3 2024 was -EUR 3 million, impacted by low volumes, high costs from underutilized capacity, and a one-off mortality cost of EUR 0.4 million.
Maintains strong stakeholder engagement and reiterates long-term growth ambitions.
Financial highlights
Q3 2024 revenue was EUR 14.3 million, down from EUR 42.0 million in Q3 2023; YTD 2024 operating income was EUR 51.6 million.
EBIT for Q3 2024: -EUR 3 million; EBIT margin was -21%, and EBIT/kg was -EUR 1.71 (or -EUR 1.46 excluding one-offs).
Equity ratio decreased to 54% at the end of September 2024.
Net interest-bearing debt, including lease liabilities, rose to EUR 89 million, mainly from increased working capital and biological asset buildup.
Paid EUR 1 million in taxes during the period, including EUR 860,000 in resource taxes.
Outlook and guidance
Volume guidance for 2024 is 13,000 tonnes, with a significant increase expected in Q4.
2025 volume guidance is 15,000 tonnes, with most harvest in the second half; 2026 volumes expected to normalize.
Long-term ambition to reach 26,000 tonnes per year within current licenses.
Contract share expected at 11% for Q4 and 12% for full year 2024.
Underlying costs expected to decrease in Q4 due to better capacity utilization and operational improvements.
Latest events from Icelandic Salmon
- Q1 EBIT neared break-even as volumes rose, with stable 2026 outlook despite lower prices.ISLAX
Q1 2026 - Q4 2025 delivered improved results and a positive outlook, with 2026 volume guidance at 21,300 tonnes.ISLAX
Q4 2025 - Operational loss from high costs, but harvest growth and 2026 recovery expected.ISLAX
Q3 2025 - Operational losses and lower guidance amid biological, regulatory, and market challenges.ISLAX
Q2 2025 - Biological setbacks drove Q2 and H1 losses, but new licenses and ASC certification support growth.ISLAX
Q2 2024 - Biological setbacks and weak prices drove a Q1 2025 loss, but 2025 guidance is unchanged.ISLAX
Q1 2025 - Stabilized Q4 operations, strong demand, and 2025 volume guidance at 15,000 tonnes.ISLAX
Q4 2024